➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
McKesson
Medtronic
McKinsey

Last Updated: June 21, 2021

DrugPatentWatch Database Preview

NEURONTIN Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Neurontin, and when can generic versions of Neurontin launch?

Neurontin is a drug marketed by Upjohn and is included in three NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has fifty-two patent family members in forty-six countries.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Neurontin

A generic version of NEURONTIN was approved as gabapentin by ACTAVIS ELIZABETH on September 12th, 2003.

  Get Started Free

Drug patent expirations by year for NEURONTIN
Drug Prices for NEURONTIN

See drug prices for NEURONTIN

Drug Sales Revenue Trends for NEURONTIN

See drug sales revenues for NEURONTIN

Recent Clinical Trials for NEURONTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pharma Guide CRON/A
CAMC Health SystemPhase 4
PfizerPhase 4

See all NEURONTIN clinical trials

Pharmacology for NEURONTIN
Paragraph IV (Patent) Challenges for NEURONTIN
Tradename Dosage Ingredient NDA Submissiondate
NEURONTIN CAPSULE;ORAL gabapentin 020235
NEURONTIN TABLET;ORAL gabapentin 020882
NEURONTIN SOLUTION;ORAL gabapentin 021129

US Patents and Regulatory Information for NEURONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993 AB RX Yes No   Get Started Free   Get Started Free   Get Started Free
Upjohn NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 AA RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Upjohn NEURONTIN gabapentin CAPSULE;ORAL 020235-002 Dec 30, 1993 AB RX Yes No   Get Started Free   Get Started Free   Get Started Free
Upjohn NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Upjohn NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998 AB RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NEURONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993   Get Started Free   Get Started Free
Upjohn NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998   Get Started Free   Get Started Free
Upjohn NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998   Get Started Free   Get Started Free
Upjohn NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998   Get Started Free   Get Started Free
Upjohn NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Merck
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.